Interested in improving #donorHeart outcomes and expanding the donor pool for #heartTransplants? N. Mondal @docnandan.bsky.social, S. Li et al have a recent paper on the topic. @apsphysiology.bsky.social @bcmhouston.bsky.social journals.physiology.org/doi/full/10....
#PaulKornerSeminar speaker @jvillanueva01 has been researching ways to increase donor heart utilisation to alleviate #transplant waitlist. Find out if #SGLT2inhibitors, typically used for #type2diabetes, can help improve #donorheart function. #WomeninSTEM #WomenInScience
#PaulKornerSeminar speaker @jvillanueva01 has been researching ways to increase donor heart utilisation to alleviate #transplant waitlist. Find out if #SGLT2inhibitors, typically used for #type2diabetes, can help improve #donorheart function. #WomeninSTEM #WomenInScience
Starting any minute now! For today’s #PaulKornerSeminar, Jeanette Villanueva @jvillanueva01 from the #TransplantationLab is tackling donor heart scarcity: Can the anti-diabetic drug #empagliflozin, an #SGLT2i, be used to help improve #donorheart preservation? #WomenInScience
Starting any minute now! For today’s #PaulKornerSeminar, Jeanette Villanueva @jvillanueva01 from the #TransplantationLab is tackling donor heart scarcity: Can the anti-diabetic drug #empagliflozin, an #SGLT2i, be used to help improve #donorheart preservation? #WomenInScience